UNSPSC 51433922: Benidipine

This classification denotes a calcium channel blocker with the molecular formula C28H31N3O6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 4G9T91JS7E, chemically known as (+-)-(r*)-3-((r*)-1-benzyl-3-piperidyl) methyl 1,4-dihydro-2,6-dimethyl-4-(m-nitrophenyl)-3,5-pyridinedicarboxylate but generally known as benidipine, which bears US NIH Compound Identifier 60065. Benidipine most often comes in base and hydrochloride forms.

UNSPSC 51433922 Benidipine is a Commodity code representing a single pharmaceutical product — a calcium channel blocker antihypertensive — but the recent state and local opportunities tagged under this code reflect broader pharmaceutical procurement patterns across emergency services, state health programs, and cooperative purchasing alliances. State and local governments buying under this code are acquiring Advanced Life Support medications for fire rescue services, managing pharmacy benefit programs for employee and retiree populations, and sourcing generic pharmaceuticals through multistate cooperative purchasing vehicles. The issuing bodies include municipal purchasing departments (City of Tampa), state health agencies (Texas Health and Human Services Commission), and cooperative purchasing alliances serving multiple jurisdictions (Minnesota Multistate Cooperative Purchasing Alliance, or MMCAP). Emergency responders and state Medicaid programs represent the primary end-user segments for pharmaceutical procurement at this level.

Geographic activity spans Florida, Texas, and Minnesota with multistate participation through MMCAP extending into Oregon. The City of Tampa's Purchasing Department issued an IFB (Bid No. 26-P-00188) on April 24, 2026, for Advanced Life Support Medications to supply Tampa Fire Rescue with labetalol, epinephrine, adenosine, and diltiazem — with electronic bids due April 8, 2026, and an estimated contract value of $40,000.00, featuring a Small Local Business Enterprise sheltered market designation with a 5 percent bid discount capped at $10,000. The Texas Health and Human Services Commission posted an RFI (HHS0017013) on April 3, 2026, to gather vendor capabilities regarding direct-to-manufacturer pharmacy programs serving self-insured employers and state agencies. MMCAP administered by Minnesota's Department of Administration issued an RFP (S1070000015802) due March 26, 2026, to establish multiple contracts for generic pharmaceuticals and OTC products through authorized wholesalers, with awards effective July 1, 2026, and a two-year term; this procurement applies performance penalties and requires vendors to maintain $2 million to $5 million in insurance coverage across commercial general liability, network security, and professional liability lines.